

# Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/M890DBB13CAEN.html>

Date: December 2019

Pages: 81

Price: US\$ 2,000.00 (Single User License)

ID: M890DBB13CAEN

## Abstracts

Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2019, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Middle East Respiratory

Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Middle East Respiratory Syndrome (MERS) - Overview
- Middle East Respiratory Syndrome (MERS) - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
  - Assessment by Target
  - Assessment by Mechanism of Action
  - Assessment by Route of Administration
  - Assessment by Molecule Type
- Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
  - Abhelix LLC
  - Anglo Biopharma Ltd
  - Atriva Therapeutics GmbH
  - Autoimmune Technologies LLC
  - Future Medicine Co Ltd
  - Gilead Sciences Inc
  - Global BioLife Inc Ltd
  - Greffex Inc
  - Humabs BioMed SA
  - Inovio Pharmaceuticals Inc
  - NanoViricides Inc
  - Novavax Inc
  - Phelix Therapeutics LLC
  - Regeneron Pharmaceuticals Inc
  - Romark Laboratories LC
  - SAB Biotherapeutics Inc
  - Signia Therapeutics
  - Sumagen Co Ltd
  - Themis Bioscience GmbH
  - Vaccitech Ltd
- Middle East Respiratory Syndrome (MERS) - Drug Profiles

Middle East Respiratory Syndrome (MERS) - Dormant Projects

Middle East Respiratory Syndrome (MERS) - Discontinued Products

Middle East Respiratory Syndrome (MERS) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Abhelix LLC, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Anglo Biopharma Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Atriva Therapeutics GmbH, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Autoimmune Technologies LLC, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Future Medicine Co Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Gilead Sciences Inc, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Global BioLife Inc Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Greffex Inc, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Humabs BioMed SA, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by NanoViricides Inc, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Novavax Inc, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Phelix Therapeutics LLC, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Romark Laboratories LC, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by SAB Biotherapeutics Inc, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Signia Therapeutics, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Sumagen Co Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Themis Bioscience GmbH, H2 2019

Middle East Respiratory Syndrome (MERS) - Pipeline by Vaccitech Ltd, H2 2019

Middle East Respiratory Syndrome (MERS) - Dormant Projects, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

## I would like to order

Product name: Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/M890DBB13CAEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M890DBB13CAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970